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Influence of Cigarette Smoking on Histological Subtypes of
Stage I Lung Adenocarcinoma
Ryo Maeda, MD,* Genichiro Ishii, MD,† Junji Yoshida, MD,* Tomoyuki Hishida, MD,*
Mitsuyo Nishimura, MD,* and Kanji Nagai, MD*
Background: The purpose of this study was to examine the asso-
ciation between cigarette smoking and histological subtypes of lung
adenocarcinoma.
Methods: We reviewed a total of 320 consecutive patients with
stage I adenocarcinoma who underwent complete resections with
systematic node dissections from January 2004 to December 2006 at
the National Cancer Center Hospital East.
Results: A statistically significant difference was observed in recur-
rence-free probabilities between never smokers and ever smokers
(3-year recurrence-free probabilities of 95.6% and 88.6%, respec-
tively, p  0.034). Among adenocarcinoma histological subtypes,
only a solid component was significantly more frequent in ever
smokers than in never smokers (p  0.001). Among patients with
solid components, significantly more cases had lymphatic perme-
ation (p  0.007), intratumoral vascular invasion (p  0.001), and
visceral pleural invasion (p  0.001). Multivariate analysis revealed
that ever-smoking history was the only statistically significant inde-
pendent clinical predictor for a solid component (p  0.001).
Among ever smokers, smoking extent in pack-years of patients with
solid components was significantly greater than that of those without
solid components (p  0.001). With respect to predominant sub-
types, smoking extent in pack-years of patients with predominantly
solid adenocarcinomas was significantly greater than that of patients
with predominantly bronchioloalveolar carcinoma, papillary, or aci-
nar adenocarcinomas (all p  0.001).
Conclusion: A greater smoking extent was associated with the
presence of adenocarcinoma solid components, which may have
more aggressive biological features resulting in poorer outcomes.
Key Words: Lung cancer, Adenocarcinoma, Subtype, Thoracic
surgery, Cigarette smoking, Solid component.
(J Thorac Oncol. 2011;6: 743–750)
Adenocarcinoma of the lung is the most frequent histolog-ical subtype of lung cancer, and its incidence is increas-
ing in most countries.1 In Japan, adenocarcinoma is also the
most common histological subtype of resected lung cancers,
accounting for more than 60% of cases.2
Adenocarcinomas are typically very heterogeneous,
showing a wide variety of histological features, including
bronchioloalveolar carcinoma (BAC), acinar, papillary, and
solid adenocarcinoma.3 Among these major histological sub-
types, BAC is often reported to be associated with a favorable
prognosis,4–6 whereas the other subtypes are considered in-
vasive components and are associated with poor outcomes,
particularly solid components.7,8
Smoking is a well-known causative factor of lung cancer9
and is associated with all the histological subtypes of lung
cancer.10–12 Although the association of cigarette smoking with
adenocarcinoma is reported to be the weakest,12 its association
with carcinogenesis of lung adenocarcinoma is established. Sev-
eral studies have recently reported that ever smokers had signif-
icantly unfavorable prognoses compared with never smokers
among patients with lung adenocarcinoma.13,14 Because the
association between smoking and postoperative complications is
well known,13,15 this factor may partially contribute to unfavor-
able cancer survivals of ever smokers. Another possible reason
is that the number of patients with BAC subtypes among never
smokers has recently increased,16 which may also partially
contribute to the favorable prognoses among never smokers.
Although many studies have reported on the associa-
tions between cigarette smoking and lung adenocarcino-
mas,13,14 several questions regarding the influence of cigarette
smoking on lung adenocarcinomas remain unanswered. Pri-
marily, whether cigarette smoking affects the biological be-
haviors of lung adenocarcinomas, especially histological sub-
types of adenocarcinoma? If so, with which subtype(s) is
cigarette smoking associated? To answer these questions, we
reviewed a series of consecutive patients with pathological
stage I adenocarcinomas who underwent complete resections
in our hospital. The main purpose of this study was to
investigate the association between cigarette smoking and the
histological subtypes of adenocarcinoma.
PATIENTS AND METHODS
Patients Selection
A total of 466 consecutive patients with clinical stage I
adenocarcinoma underwent operation from January 2004 to
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December 2006 at the National Cancer Center Hospital East.
We excluded three patients from our study because they had
received preoperative chemotherapy, radiation therapy, or
both. Among the 463 patients, 458 patients underwent com-
plete surgical resection. The operative findings and patholog-
ical examination of surgical specimens revealed that 90
patients were reclassified as pathological stage II or higher
and were up-staged. Among the 368 patients diagnosed as
pathological stage I, 48 patients underwent limited surgery.
The remaining 320 patients with pathological stage I adeno-
carcinoma who underwent complete tumor resection with
lobectomy or a more extensive surgery along with systematic
lymph node dissection were enrolled as the subjects of this
study.
Pathological Evaluations
Disease stages were diagnosed based on the TNM
classification of the International Union Against Cancer, 7th
edition.17 The histological type was determined according to
the World Health Organization’s classification.3 Intratumoral
vascular invasion (IVI) and visceral pleural invasion (VPI)
were evaluated by staining with hematoxylin-eosin and Vic-
toria blue-van Gieson stains. VPI was classified according to
the TNM classification, 7th edition.17 Adenocarcinoma his-
tological subtypes were categorized into BAC (nonmucinous
or mucinous), papillary, acinar, and solid adenocarcinomas
according to the World Health Organization’s classification.3
Mucin production in a solid adenocarcinoma component was
confirmed by the alcian blue-periodic acid Schiff method. We
determined the predominant subtype, and each component
was defined as present if observed in more than 1 of 10 of a
tumor; otherwise, it was defined as absent.
Clinicopathological Information
We prospectively collected information on cigarette
smoking status using outpatient clinic questionnaires, which
were answered by patients on their first clinic visit. Patients
were asked to record the age when they started smoking,
duration of smoking, and average daily cigarette consump-
tion. No environmental cigarette smoke exposure data were
collected. The extent of smoking was quantified in pack-years
(PY), with 1 PY equivalent to 20 cigarettes, on average, per
day for 1 year. Before admission, all patients were required to
stop smoking.
We reviewed the medical records of each patient for
clinicopathological information. This included age (dichoto-
mized at the median age of 65 years), gender, smoking
history (never- or ever smoker), smoking extent in PY, forced
expiratory volume in 1 second % (70% or 70%), preop-
erative serum carcinoembryonic antigen (CEA) level (cutoff
at the normal upper limit of 5 ng/ml), tumor laterality (right
or left), primary lobe (upper, middle, or lower lobe), tumor
size (3 cm or3 cm), BAC component (present or absent),
papillary component (present or absent), acinar component
(present or absent), solid component (present or absent),
predominant histological subtypes (BAC, papillary, acinar, or
solid), lymphatic permeation (present or absent), IVI (present
or absent), and VPI (as defined in the TNM classification, 7th
edition,17 present or absent).
Statistical Analysis
Differences in categorical outcomes were evaluated by
2 test. Continuous variables were compared using t tests. To
offset the prognostic impact of comorbidities associated with
cigarette smoking, we investigated recurrence-free probabil-
ities for this study. The length of recurrence-free probability
was calculated in months from the date of resection to the
date of first recurrence or last follow-up. To calculate the
recurrence-free probability, patients who died without recur-
rence or who were known to be recurrence free at the date of
last contact were excluded from the calculation. For univar-
iate analyses, all recurrence-free probabilities were estimated
using the Kaplan–Meier method, and comparisons of these
variables were made using the log-rank test. Multivariate
analyses were performed using Cox’s proportional hazard
regression model. Clinical predictors for the presence of a
solid component were evaluated by logistic regression anal-
yses. The predictors from univariate analyses were also
evaluated using multiple regression analyses. The p value less
than 0.2 in a univariate model was set as the threshold used
for selection of variables in a multivariate model. All reported
p values were two sided, and the significance level was set at
less than 0.05. Analyses were performed using SPSS version
11.0 (Dr. SPSS II for Windows, standard version 11.0, SPSS
Inc., Chicago, IL) and GraphPad Prism (Prism for Windows,
Version 5.02, GraphPad Software, Inc., La Jolla, CA).
Data collection and analyses were approved, and the
need to obtain written informed consent from each patient
was waived by the institutional review board in April 2010.
RESULTS
Patient Characteristics and Recurrence-Free
Probabilities According to Clinicopathological
Factors
The median follow-up period was 37 months (range:
3–60 months). Recurrence-free probabilities according to
clinicopathological factors are presented in Table 1. Univar-
iate analysis (log-rank test) identified eight significant risk
factors for recurrence: gender, smoking history, preoperative
serum CEA level, tumor diameter, the presence of solid
component, lymphatic permeation, IVI, and VPI (Table 1).
A statistically significant difference was observed in
recurrence-free probabilities between never smokers and ever
smokers: 3-year recurrence-free probabilities of 95.6% and
88.6%, respectively (Figure 1). Figures 2A–D show the re-
currence-free probability curves according to the histological
subtypes. No statistically significant differences were present
in the recurrence-free probabilities between patients with and
without BAC (3-year recurrence-free probabilities of 90.2%
and 92.9%, respectively; p  0.522; Figure 2A), with and
without papillary (88.8% and 93.2%, respectively; p 0.539;
Figure 2B), and with and without acinar (95.2% and 88.9%,
respectively; p  0.092; Figure 2C) components. In con-
trast, the 3-year recurrence-free probability for patients
with solid components (84.9%) was significantly lower
than that for those without solid components (96.3%; p 
0.001; Figure 2D).
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65 169 (53) 93.5 0.534 Not included multivariable model
65 151 (47) 90.5
Gender
Women 175 (55) 95.8 0.009* 1
Men 145 (45) 87.4 1.282 0.330–4.986 0.72
Smoking history
Never-smoker 148 (46) 95.6 0.034* 1
Ever-smoker 172 (54) 88.6 1.644 0.354–7.629 0.525
CEA
Within normal range 148 (46) 94.9 0.007* 1
Elevated 172 (54) 85 1.221 0.499–2.989 0.661
FEV1 %
70 277 (87) 92.8 0.591 Not included multivariable model
70 42 (13) 87.9
Tumor laterality
Right 206 (64) 93.5 0.499 Not included multivariable model
Left 114 (36) 90
Primary lobe
Upper or middle lobe 227 (71) 93.3 0.297 Not included multivariable model
Lower lobe 93 (29) 89.4
Tumor size (cm)
3.0 253 (79) 96.4 0.015* 1
3.0 67 (21) 89.5 1.165 0.393–3.457 0.783
Histological subtypes
BAC component
Absent 95 (30) 90.2 0.522 Not included multivariable model
Present 225 (70) 92.9
Papillary component
Absent 83 (26) 88.8 0.539 Not included multivariable model
Present 237 (74) 93.2
Acinar component
Absent 163 (51) 95.2 0.092 1
Present 157 (49) 88.9 1.151 0.474–2.797 0.756
Solid component
Absent 199 (62) 96.3 0.001* 1
Present 121 (38) 84.9 1.59 0.661–3.823 0.301
Pathological factors
Lymphatic permeation
Absent 297 (93) 94.8 0.001* 1
Present 23 (7) 58.4 2.698 1.050–6.932 0.039*
Intratumoral vascular invasion
Absent 245 (77) 98.6 0.001* 1
Present 75 (23) 70.9 14.65 3.804–56.422 0.001*
Visceral pleural invasion
Absent 261 (82) 95.5 0.001* 1
Present 59 (18) 77.9 1.006 0.393–2.581 0.989
Gene mutation status
EGFR
Wild type 71 (22) 87.7 0.783 Not included multivariable model
Mutated 12 (4) 90
Not examined 237
*, significance; Numbers in parentheses, percentages; †, log-rank test; HR, hazard ratio; CI, confidence interval; CEA, preoperative serum carcinoembryonic antigen level, normal
upper limit at 5 ng/mL; FEV1%, forced expiratory volume % in one second; BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor.
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On multivariate analysis using the Cox regression
model, presence of lymphatic permeation and presence of IVI
remained statistically significant independent predictors for
postoperative recurrence after resection (Table 1).
Univariate and Multivariate Analyses of Clinical
Predictors for the Presence of a Solid
Component
Because of the significantly lower recurrence-free prob-
ability only for patients with solid components among ade-
nocarcinoma histological subtypes, we examined clinical pre-
dictors for the presence of a solid component. Univariate
analyses revealed three significant clinical predictors for the
presence of a solid component: gender, smoking history, and
CEA (Table 2). On multivariate analysis, ever-smoking his-
tory was the only statistically significant independent clinical
predictor for the presence of a solid component (p  0.001;
Table 2).
Associations between Solid Components and
Other Pathological Factors
To clarify the reasons why patients with solid compo-
nents had the significantly lower recurrence-free probability
compared with those without solid components, we examined
FIGURE 1. Recurrence-free probability curves according to
smoking history in the entire cohort.
FIGURE 2. Recurrence-free probability curves according to the histological subtypes in the entire cohort. A, Recurrence-free
probability curves of patients with and without bronchioloalveolar carcinoma (BAC) components. B, Recurrence-free probabil-
ity curves of patients with and without papillary components. C, Recurrence-free probability curves of patients with and with-
out acinar components. D, Recurrence-free probability curves of patients with and without solid components.
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associations between solid components and pathological fac-
tors including statistically significant independent predictors
for recurrence such as lymphatic permeation and IVI (Ta-
ble 3). Among patients with solid components, significantly
more cases were found with lymphatic permeation (p 
0.007), IVI (p  0.001), and VPI (p  0.001). In addition,
significantly more cases with epidermal growth factor recep-
tor (EGFR) mutations were found in patients without solid
components (p  0.033).
Associations between Smoking History or
Smoking Extent and Adenocarcinoma
Histological Subtypes
The presence of a solid component was strongly asso-
ciated with cigarette smoking (Table 2). Further evaluations
were performed for elucidating the association between cigarette
smoking and histological subtypes other than solid components
in addition to other pathological factors (Table 4).
A BAC or papillary component was significantly more
frequent in never smokers than in ever smokers (p  0.001
and p  0.01, respectively; Table 4). Among ever smokers,
significantly more cases were found with IVI (p  0.025). In
addition, significantly more cases with EGFR mutations were
found in never smokers (p  0.001).
Figures 3A–D show the associations between smoking
extent and histological subtypes for ever smokers only. In
ever smokers only, the smoking extent in PY of patients with
BAC components (mean  25.0  2.5) was significantly
lower than that of those without BAC components (mean 
44.9  3.8; Figure 3A). In contrast, the smoking extent in PY
of patients with solid components (mean  45.2  3.2) was
significantly greater than for those without solid components
(mean  30.0  2.7; p  0.001; Figure 3D).
Figure 4 shows the smoking extent in PY of all patients
stratified by their predominant histological subtypes. The
smoking extent in PY of patients with predominantly solid
adenocarcinomas (PY 45.5 4.5) was significantly greater
than that of those with predominantly BAC (PY  14.5 
2.2), papillary (PY  16.6  2.4), or acinar (PY  23.5 
4.7) adenocarcinomas (all p  0.001).
Figure 5 shows the association between smoking extent
and the proportions of tumors with solid components in the
entire study cohort. Patients with higher proportions of solid
tumor components also had greater smoking extent in PY.
The smoking extent in PY of patients who had tumors with
more than 50% solid components was greater than that of
patients who had tumors with 10 to 50% solid components
TABLE 2. Univariate and Multivariate Analyses of Predictors for the Presence of a Solid Component
Variables
Univariate Analysis Multivariate Analysis
HR 95% CI pa HR 95% CI pb
Age (yr)
65 1.37 0.871–2.156 0.173 1.423 0.859–2.359 0.642
65 1 1
Gender
Male 3.182 1.988–5.092 0.001c 1.543 0.852–2.795 0.152
Female 1 1
Smoking habits
Ever smoker 4.419 2.680–7.287 0.001c 3.319 1.779–6.191 0.001c
Never smoker 1 1
CEA
Elevated 2.103 1.222–3.316 0.001c 1.517 0.872–2.639 0.14
Within normal range 1 1
FEV1%
70 1.798 0.936–3.454 0.078 1.032 0.495–2.155 0.933
70 1 1
Tumor laterality
Right 1.182 0.739–1.890 0.486 Not included in multivariable model
Left 1
Primary lobe
Upper or middle lobe 1.079 0.654–1.776 0.767 Not included in multivariable model
Lower lobe 1
Tumor size (cm)
3.0 1.443 0.836–2.491 0.187 1.156 0.629–2.124 0.742
3.0 1 1
a Logistic regression procedure.
b Multiple regression analysis.
c Significance.
CEA, preoperative serum carcinoembryonic antigen level, normal upper limit at 5 ng/ml; FEV1%, forced expiratory volume % in 1 second; HR, hazard
ratio; CI, confidence interval.
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(p  0.001) and patients who had tumors without solid
components (p  0.001).
DISCUSSION
Cigarette smoking is a well-known risk factor for lung
carcinogenesis.9 Recent studies have indicated that ever
smokers show significantly unfavorable prognoses, when
compared with never smokers, particularly those with adeno-
carcinomas.13,14 It has been suggested that cigarette smoking
is associated with not only lung carcinogenesis but also
unfavorable prognoses for lung adenocarcinomas. One pos-
sible reason why smokers with lung adenocarcinomas had
more unfavorable prognoses than never smokers in previous
reports13 is that cigarette smoking is strongly associated with
factors such as low socioeconomic status,18 poor nutrition,19
comorbidities,20 and impaired immune function.21 These
smoking-associated factors may contribute to poor survival
rates of cigarette smokers after lung cancer resections. Nev-
ertheless, in this study, ever smokers had a significantly lower
recurrence-free probability compared with never smokers
with stage I adenocarcinomas, which suggests that smoking-
related lung adenocarcinomas may behave more aggressively
or result in unfavorable survival, regardless of cigarette
smoking-related comorbidities.
The histological subtypes of adenocarcinoma mainly
comprised BAC, acinar, papillary, and solid components.3
Adenocarcinomas are histologically very heterogeneous, with
only a minority of cases showing pure histological patterns.3
Among these components, a solid component is the most
poorly differentiated subtype.22,23 Several studies have re-
ported that the presence of a solid component is indicative of
tumor invasiveness, proliferation, and dedifferentiation.22,23
Riquet et al.22 reported that patients with solid components
have significantly poorer outcomes compared with those
without solid components among patients with stage I ade-
nocarcinoma. Also in this study, the 3-year recurrence-free
probability for patients with solid components was signifi-
cantly lower than that for patients without solid components.
In this study, the presence of a solid component was
more frequently associated with an invasive or aggressive
pathologic status, including lymphatic permeation, IVI, and
VPI. This indicates that the presence of a solid component
induces a more invasive and aggressive nature of lung ade-
nocarcinomas, which is reflected by worse outcomes. There
may be several possible explanations for the more aggressive
and invasive biological characteristics of solid components
observed in this study. Ding et al.24 reported that mutations in
the p53 gene were negatively correlated with acinar, papil-
lary, and BAC subtypes but were significantly positively








Total 320 199 121
Pathological factors
Lymphatic permeation
Absent 297 191 (64) 106 (36) 0.007b
Present 23 8 (35) 15 (65)
Intratumoral vascular invasion
Absent 245 171 (70) 74 (30) 0.001b
Present 75 28 (37) 47(63)
Visceral pleural invasion
Absent 261 176 (67) 85 (33) 0.001b
Present 59 23 (39) 36 (61)
Gene mutation status
EGFR
Wild type 71 35 (49) 36 (51) 0.033b
Mutated 12 10 (83) 2 (17)
Not examined 237
Numbers in parentheses represent percentages.
a 2 test.
b Significance.
EGFR, epidermal growth factor receptor.











Total 320 148 172
Histological subtypes
BAC component
Absent 95 23 (24) 72 (76) 0.001b
Present 225 125 (56) 100 (44)
Papillary component
Absent 83 28 (34) 55 (66) 0.01b
Present 237 120 (51) 117 (49)
Acinar component
Absent 163 74 (45) 89 (55) 0.823
Present 157 74 (47) 83 (53)
Solid component
Absent 199 118 (59) 81 (41) 0.001b
Present 121 30 (25) 91 (75)
Pathological factors
Lymphatic permeation
Absent 297 138 (46) 159 (54) 0.831
Present 23 10 (43) 13 (57)
Intratumoral vascular invasion
Absent 245 122 (50) 123 (50) 0.025b
Present 75 26 (35) 49 (65)
Visceral pleural invasion
Absent 261 123 (47) 138 (53) 0.564
Present 59 25 (42) 34 (58)
Gene mutation status
EGFR
Wild type 71 22 (31) 49 (69) 0.001b
Mutated 12 10 (83) 2 (17)
Not examined 237
Numbers in parentheses represent percentages.
a 2 test.
b Significance.
BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor.
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correlated with solid subtypes of pulmonary adenocarcino-
mas. Suzuki et al.25 reported that tumors with p53 gene
alterations showed higher growth fraction percentages, which
may be the reason why a solid component was more aggres-
sive and invasive and resulted in worse outcomes.
Suzuki et al.25 also reported that a p53 mutation in lung
cancer is closely associated with lifetime cigarette consump-
tion. In this study, a solid component was more likely to be
present in ever smokers than in never smokers. When eval-
uating ever smokers only, the smoking extent in PY of
patients with solid components was significantly greater than
that of those without solid components, which demonstrated
that the presence of a solid component was strongly associ-
ated with a greater smoking extent.
In this study, ever-smoking history was a strong clinical
predictor for the presence of a solid component. Several
researchers have recently reported successful results with
limited surgical resections for small adenocarcinomas.26–30
Nevertheless, locoregional recurrence after limited resection
is not rare, even in patients with a pathologically confirmed
negative surgical margin.31 This is probably due to intratu-
moral vessel involvement.32 The presence of a solid compo-
nent was significantly associated with histologically invasive
characteristics such as lymphatic permeation, IVI and VPI,
and it may be prudent to avoid limited surgery for patients
with these invasive components. Therefore, we should be
careful when proposing limited surgery for patients with
FIGURE 3. Associations between smoking extent and histological subtypes among ever smokers only. A, Bronchioloalveolar
carcinoma (BAC) components. B, Papillary components. C, Acinar components. D, Solid components.
FIGURE 4. Smoking extent in pack-years (PY) of patients
stratified according to predominant histological subtypes. FIGURE 5. Association between smoking extent and the
proportions of solid tumor components in the entire cohort.
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adenocarcinoma with smoking histories, particularly those
with greater smoking extent.
In this study, significantly more cases with EGFR
mutations were found in never smokers and patients without
solid components. Ding et al.24 reported that an EGFR mu-
tation showed significant positive correlations with BAC
and papillary subtypes but not with the solid subtype. In
this study, a BAC or papillary component was significantly
more frequent in never smokers than in ever smokers. In
contrast, significantly more patients with solid components
were found among ever smokers. The associations between
adenocarcinoma histological subtypes and cigarette smok-
ing demonstrated by our study may partly explain why
EGFR mutations tended to be more frequent in the adeno-
carcinomas of never smokers than those of ever smokers in
previous studies.33
This was a retrospective study, and the analyses con-
ducted had several limitations. In particular, smoking extent
was reported by the patients but was not confirmed biochem-
ically and, therefore, may be biased. Objective quantification
of environmental cigarette smoke exposure was difficult and
was, therefore, not included in the analyses. Another limita-
tion was a lack of ethnic diversity in our 100% Japanese
patient population. Despite these limitations, we have clearly
shown the influence of cigarette smoking on lung adenocar-
cinomas, particularly the associations between cigarette
smoking and adenocarcinoma histological subtypes.
CONCLUSION
A greater smoking extent is associated with the pres-
ence of a solid tumor component, which may have more
aggressive biological features and result in poorer outcomes.
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